CertiK Unveils SkyInsightsTM: A Game-Changer in Crypto Compliance and Risk Management 13-09-2023, 12:36

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Horizon Group USA Accelerates Global Growth Strategy with Expanded Leadership 13-11-2024, 20:00